ライフサイエンスコーパス: final diagnosis

1 ts (celiac disease, no celiac disease, or no final diagnosis).

2 All images led to a clear final diagnosis.

3 e diagnosis or 2-y follow-up established the final diagnosis.

4 eriappendiceal inflammation was used for the final diagnosis.

5 Histology or clinical follow-up was used for final diagnosis.

6 and a more accurate physician impression of final diagnosis.

7 n between clinical and CT parameters and the final diagnosis.

8 bability of the patient having CHF and their final diagnosis.

9 nd not to have celiac disease, and 24 had no final diagnosis.

10 position, problems occurred in determining a final diagnosis.

11 ogic subtype, tissue biopsy is necessary for final diagnosis.

12 for the distribution of changes, and likely final diagnosis.

13 consensus readings were correlated with the final diagnosis.

14 rns were reviewed and were compared with the final diagnosis.

15 D) and yet were found to have an alternative final diagnosis.

16 s, biochemical workup, any intervention, and final diagnosis.

17 y, an additional CT test enables stating the final diagnosis.

18 hecal and systemic immunity, irrespective of final diagnosis.

19 es ECPW examination proved conclusive to the final diagnosis.

20 pectively reviewed by a grader masked to the final diagnosis.

21 erienced technicians masked to the patients' final diagnosis.

22 ed by comparing EBUS-TBNA diagnosis with the final diagnosis.

23 rcolepsy were compared within group by their final diagnosis.

24 y were calculated by comparing findings with final diagnosis.

25 m shown in the imaging studies confirmed our final diagnosis.

26 s with serial changes was compared against a final diagnosis adjudicated by 2 independent cardiologis

27 An expert panel assigned final diagnosis after 3 months.

28 Uncertainty about the final diagnosis after LCBB is associated with substantia

29 ysis were used to identify predictors of the final diagnosis among several variables.

30 diagnosis in 65% of cases; but agreement on final diagnosis among the four pathologists was complete

31 en than in men in terms of time to reach the final diagnosis and downstream testing.

32 h the role of radiological procedures in the final diagnosis and further treatment of such cases.

33 of other confounders including age, gender, final diagnosis and thrombolysis treatment (odds ratio [

34 er small bowel transplantation, the work-up, final diagnosis, and evolution.

35 ry CT signs of mediastinitis and a different final diagnosis, and those with neither primary CT findi

36 Primary outcomes were final diagnosis, antibiotic use, and need for hospitaliz

37 differential diagnosis, neuropathology, and final diagnosis are discussed here.

38 logic decline, neuropathologic findings, and final diagnosis are discussed.

39 erential diagnosis, pathologic findings, and final diagnosis are discussed.

40 Physicians indicated the correct final diagnosis as most likely among their viable diagno

41 on on specimen radiographs was compared with final diagnosis at surgical excision.

42 ther diagnostic algorithm or, in many cases, final diagnosis based exclusively on an MRI examination.

43 nostics and, in many cases, establishing the final diagnosis based on MR examination.

44 e both independent variables associated with final diagnosis, but lesion size was not an independent

45 Final diagnosis by allergists was considered the referen

46 The proportion of patients with a final diagnosis by EBUS-TBNA in whom subtype was classif

47 with findings from MR imaging and CT and the final diagnosis by means of logistic regression.

48 over the same period who had an alternative final diagnosis (CJD mimics).

49 llent concordance with the blinded consensus final diagnosis (Cohen k = 0.80).

50 ths to 5 years following biopsy to determine final diagnosis, delayed complications, and influence of

51 c information has the greatest impact on the final diagnosis, especially when the initial clinical/ra

52 ologic and microbiologic confirmation of the final diagnosis, formed the basis of this investigation.

53 In 53 patients (80%) with lymphoma as a final diagnosis, histologic subclassification was suffic

54 Final diagnosis: hypersensitivity pneumonitis in 47.3% (

55 Appendicitis was the final diagnosis in 118 cases.

56 AMI was the adjudicated final diagnosis in 127 patients (15%); cardiac noncorona

57 AMI was the final diagnosis in 156 patients (7.9%).

58 Acute myocardial infarction was the final diagnosis in 36% of all patients with renal dysfun

59 te hepatitis C virus (HCV) infection was the final diagnosis in 4 of 9 unlikely cases.

60 atients, acute myocardial infarction was the final diagnosis in 451 (16%) patients.

61 oximately 10 times more likely than a benign final diagnosis in participants with PET results rated d

62 malignancy, there was a significant delay to final diagnosis in the CT group compared with the (18)F-

63 , electron microscopy was needed to make the final diagnosis; in two of these cases, the preliminary

64 % at US; 82 of 109, 75% at MR) than when the final diagnosis included other anomalies as well (14 of

65 The final diagnosis is always based on histopathological exa

66 Final diagnosis is established with immunohistochemical

67 to an appropriate differential diagnosis and final diagnosis is highlighted in our case report.

68 Final diagnosis is made on full-thickness biopsy.

69 The final diagnosis is more quickly achieved in patients whe

70 based on SD OCT alone was compared with the final diagnosis made using ICGA and fluorescein angiogra

71 ity of MCAS, and thus establishing the exact final diagnosis, may greatly help in the management and

72 These abnormalities were compared with the final diagnosis obtained from the medical records, inclu

73 ery with histologic confirmation established final diagnosis of abnormal middle ear cleft soft tissue

74 sitivity of BMIPP by 3 blinded readers for a final diagnosis of ACS and intermediate likelihood of AC

75 ted stroke in 14 patients, all of whom had a final diagnosis of acute stroke.

76 he children, including 79 (92%) of 86 with a final diagnosis of AHO.

77 The final diagnosis of AMI was independently adjudicated usi

78 women (14.5%) and 345 men (18.6%) received a final diagnosis of AMI.

79 greater was significantly correlated with a final diagnosis of BD (p<0.05; area under the curve (AUC

80 A final diagnosis of BMI was considered if the BMB was pos

81 Two (1.2%) of 161 lesions with a final diagnosis of carcinoma were benign at LCNB but mal

82 s between expert fetal cardiac diagnosis and final diagnosis of CHD and their impact on neonatal and

83 Of the 452 patients with a final diagnosis of CHF, 165 (36.5%) had preserved left v

84 A final diagnosis of CNS, complicated with peritonitis tra

85 2-dimensional echocardiography and who had a final diagnosis of CP (n=28), RCM (n=30), or no structur

86 A final diagnosis of Crohn's disease, type of reservoir (J

87 sensitivity and specificity calculations was final diagnosis of CS injury at the time of discharge.

88 l and radiological database of patients with final diagnosis of CVT was analyzed.

89 lacrimal gland involvement, of whom 7 had a final diagnosis of GPA.

90 ar CT and MR scan reformations helped to the final diagnosis of hemangioma, showing its origin from t

91 nd 3 of colorectal cancer in patients with a final diagnosis of IE.

92 A final diagnosis of infection was based on microbiologic

93 A final diagnosis of infection was confirmed in 31 patient

94 The final diagnosis of infection was established by the IE S

95 Significantly fewer individuals received a final diagnosis of LTBI in the post-QFT-GIT period (397/

96 8%) of those receiving QFT-GIT testing had a final diagnosis of LTBI, while 167/168 (99%) of those wi

97 men radiographs were more likely to enable a final diagnosis of malignancy than were cores without ca

98 diagnosis: those with primary CT signs and a final diagnosis of mediastinitis, those with primary CT

99 those with neither primary CT findings nor a final diagnosis of mediastinitis.

100 andomly assigned to a treatment group with a final diagnosis of mesothelioma).

101 antibodies to clustered AChRs, and 42 had a final diagnosis of MG.

102 r narcolepsy) were compared within groups by final diagnosis of narcolepsy/hypocretin deficiency.

103 Final diagnosis of NET recurrence was determined in 29 p

104 ral segments, AQP4-IgG seropositivity, and a final diagnosis of NMO or NMOSD.

105 All patients with a final diagnosis of non-prion disease (71 CSF and 67 OM s

106 ters were evaluated in 1,178 patients with a final diagnosis of NSTEMI presenting <24 h after symptom

107 The final diagnosis of positive PET lesions was based on his

108 positive in the remaining 9 patients with a final diagnosis of possible IMD at the end of the study.

109 In 15 of 24 patients with a final diagnosis of possible IMD, CTPA findings were nega

110 From 355 cases with final diagnosis of PTB, 263 (71.8%) had definite diagnos

111 tly higher than the group of patients with a final diagnosis of pulmonary disease (n = 85) whose BNP

112 Correlations between RT-QuIC results and the final diagnosis of recruited patients.

113 g noncaseating granulomas in patients with a final diagnosis of sarcoidosis.

114 Twenty-nine patients had a final diagnosis of SBO, and 71 patients did not.

115 G-appropriate patients, only 247 (82%) had a final diagnosis of STEMI.

116 d for analysis, including 55 patients with a final diagnosis of stroke.

117 athologic information that substantiated the final diagnosis of the cause of death.

118 gnificant amount of information facilitating final diagnosis of the cause of IDDS therapy failure.

119 llow-up record was not yet available and the final diagnosis of the detected lesion has not yet been

120 There was a definitive final diagnosis of the nature of the mass lesions in 21

121 The final diagnosis of the qualifying event was cerebral isc

122 In most cases, the final diagnosis of the type of colitis is based on clini

123 tire cohort and for only the patients with a final diagnosis of vasculitis.

124 and 29% to 75% for only the patients with a final diagnosis of vasculitis.

125 ompletion of the trial, without knowledge of final diagnosis or outcome, the investigators classified

126 correlation between the CT diagnosis and the final diagnosis regarding the level and type of obstruct

127 charged from the hospital during 1993 with a final diagnosis-related groups code of 483.

128 Compared with the final diagnosis, single-plane digital pulmonary angiogra

129 However, final diagnosis still remains surgical even though imagi

130 pre-operative evaluation of cystic thymoma, final diagnosis still remains surgical.

131 ir diagnostic procedures repeated and have a final diagnosis that differs from that of the referring

132 211 adnexal masses were correlated with the final diagnosis; the most discriminating features for ma

133 ng three groups: patients who did not have a final diagnosis (uncertain group), patients who knew the

134 The final diagnosis was a type of FDEIA caused by 39 kDa and

135 rological evaluation excluded paralysis, our final diagnosis was ACC type VII.

136 The final diagnosis was adenoma in 127 masses and non-adenom

137 The final diagnosis was adjudicated by 2 independent cardiol

138 The final diagnosis was adjudicated in patients presenting w

139 Final diagnosis was allergic fungal rhinosinusitis (AFRS

140 Final diagnosis was AMI in 340 patients (17%).

141 A malignant final diagnosis was approximately 10 times more likely t

142 Correct final diagnosis was attained in 97 (88%) patients.

143 In 82 patients in whom a final diagnosis was available, the sensitivity, specific

144 Final diagnosis was based on a combination of EUS-FNA, s

145 lectrocardiograms, and troponin, whereas the final diagnosis was based on all available data (includi

146 The final diagnosis was based on chart review at a minimum 1

147 Final diagnosis was based on clinical follow-up, cytolog

148 The final diagnosis was based on histopathological examinati

149 marily medical management as "probable IAC," final diagnosis was CCa (n = 3) and IAC (n = 9), while 1

150 The final diagnosis was centrally adjudicated by 2 independe

151 Interventions: The final diagnosis was centrally adjudicated by 2 independe

152 The final diagnosis was centrally adjudicated by 2 independe

153 The final diagnosis was CHF in 722 (47%) participants.

154 t died 22 years after symptom onset, and the final diagnosis was confirmed at autopsy.

155 The final diagnosis was confirmed by a biopsy.

156 typical features of PD were included if the final diagnosis was confirmed by a suitable criterion st

157 The final diagnosis was confirmed with histopathologic exami

158 The final diagnosis was defined according to the clinical an

159 When the final diagnosis was determined from pathology reports, c

160 Final diagnosis was determined with histopathologic veri

161 The final diagnosis was dyspnea due to congestive heart fail

162 Final diagnosis was established after extended diagnosti

163 Final diagnosis was established at surgery (n = 29) and

164 The final diagnosis was established based on selective angio

165 Final diagnosis was established with pathologic analysis

166 The final diagnosis was established with surgical resection

167 Final diagnosis was established with surgical, pathologi

168 with confidence to have a small VSD, but the final diagnosis was intermediate VSD in 4, innocent murm

169 Consensus was more likely when the final diagnosis was isolated VM (83 of 104, 80% at US; 8

170 to assess growth in 13 patients for whom the final diagnosis was known and whose initial nodule diame

171 The final diagnosis was made by histopathology in 22 patient

172 A final diagnosis was made by surgical exploration or clin

173 lectron microscopy was then performed, and a final diagnosis was made.

174 elated with histopathological findings and a final diagnosis was made.

175 s specialists for an average of 2.2 y before final diagnosis was made.

176 The final diagnosis was obtained by pathologic (n = 56) or c

177 The final diagnosis was obtained by pathology (n = 44) or cl

178 The final diagnosis was pancreatic malignancy (n = 60), acut

179 g tests for PE were obtained and whether the final diagnosis was PE.

180 Final diagnosis was reached by consensus (198 US, 198 MR

181 These findings were confirmed when the final diagnosis was readjudicated with the use of hs-cTn

182 ticipated in the imaging experiment prior to final diagnosis was tracked and diagnoses confirmed at a

183 The final diagnosis was verified only in 83 patients.

184 bution of PET and morphologic imaging to the final diagnosis were assessed.

185 Cells indicating the final diagnosis were contained in 249 (75%) of 334 speci

186 nces, cardiac CT led in both sexes to a fast final diagnosis when compared with functional testing, a

187 ty and the specificity of MR imaging for the final diagnosis with the potential for a substantial dos